{
    "nct_id": "NCT05644561",
    "official_title": "A Phase 3, Open-label, Single-arm, Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy, Safety, and Immunogenicity of Ravulizumab Administered Intravenously in Pediatric Participants (6 to < 18 Years of Age) With Generalized Myasthenia Gravis (gMG)",
    "inclusion_criteria": "* Diagnosis of gMG confirmed by a positive serologic test for anti-AChR antibodies (Abs) obtained at Screening and/or during Screening Period\n* Myasthenia Gravis Foundation of America (MGFA) Clinical Classification of Class II to Class IV at Screening\n* Participants receiving treatment must be on a stable dosing regimen of adequate duration prior to Screening and during the Screening Period.\n* Eculizumab-experienced participants must have been enrolled and treated with eculizumab in Study ECU-MG-303 for at least 6 months (180 days) and must have been on a stable dose for â‰¥ 2 months (60 days) prior to Screening.\n* All participants must be vaccinated against meningococcal infection\nHealthy volunteers allowed",
    "exclusion_criteria": "Medical Conditions\n\n* Any untreated thymic malignancy, carcinoma, or thymoma.\n* Participants with a history of treated benign thymoma\n* History of thymectomy, thymomectomy, or any thymic surgery within the 12 months prior to Screening\n* History of N meningitidis infection\n* Known to be human immunodeficiency virus (HIV) positive\n* History of unexplained infections\n* Known or suspected history of drug or alcohol abuse or dependence within 1 year prior to the start of the Screening Period",
    "miscellaneous_criteria": ""
}